/
Immunology
Alopecia Areata
26
Pipeline Programs↗
43
Active Trials↗
25
Companies Involved↗
Alopecia Areata is an emerging landscape with 26 programs across 25 companies. The most active players are Pfizer, Sun Pharmaceutical Industries, Inc., Santen Pharmaceutical Co., Ltd.. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 25
Phase 310
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
20 of 22 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 88% of 26 pipeline programs.
Analysis
Trial Status
143
clinical trials
Completed65 · 45%
Recruiting21 · 15%
Unknown status19 · 13%
Not yet recruiting11 · 8%
Active, not recruiting11 · 8%
Terminated11 · 8%
Other5 · 3%
Clinical Trials
Trial Activity
143 trials
A Study of LAD603 in Adults With Alopecia Areata
Recruiting·—·Phase 2·NCT07311564·136 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)